Low-density lipoprotein cholesterol (LDL-C) reduction with statins is the cornerstone of atherosclerotic cardiovascular disease (CVD) prevention. The LDL-C lowering non-statin therapy ezetimibe also modestly reduces CVD risk when added to statin therapy. There remains a clinical need for additional LDL-C lowering agents to reduce CVD risk in patients with genetic hypercholesterolemia, statin intolerance, or who are at high risk due to clinical CVD or diabetes. In clinical trials proprotein convertase subtilisin/kexin type 9,( PCSK9) inhibition using monoclonal antibodies has demonstrated robust LDL-C lowering efficacy of 50% to 65% and a favorable safety profile. These agents are a promising therapeutic strategy for addressing the unmet needs for additional CVD risk reduction. Regulatory approval for PCSK9 monoclonal antibodies may occur in the near future, and additional agents for PCSK9 inhibition are under development. This review focuses on the mechanism of LDL-C reduction using PCSK9 inhibition, as well as the Phase I to III clinical trials of PCSK9 inhibitors. Results of the ongoing Phase III CVD outcomes trials are eagerly awaited.
Pharmacology, Toxicology and Pharmaceutical Science
9
10%
Unspecified
5
5%
Other
4
4%
Unknown
23
25%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2026.
All research outputs
#3,726,447
of 28,829,220 outputs
Outputs from Progress in Cardiovascular Diseases
#256
of 1,274 outputs
Outputs of similar age
#41,958
of 283,556 outputs
Outputs of similar age from Progress in Cardiovascular Diseases
#4
of 10 outputs
Altmetric has tracked 28,829,220 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,274 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.4. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,556 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.
